New Hope for Highly Dependent and Heavy Smokers
December 08, 2017
GSK Consumer Healthcare Stop-Smoking Products Significantly Increase Quit Rate for Smokers Who Need to Quit the Most
- An article in the current issue of the Journal of Substance Abuse Treatment (Volume 28, Issue 1, 2005) provides new hope for smokers who are highly dependent upon tobacco and who smoke more than two packs per day. Researchers examined data from two previous clinical trials and found that the 21 mg NicoDermâ CQâ patch and the 4 mg Commitâ lozenge marketed by GlaxoSmithKline (GSK) Consumer Healthcare can significantly increase the most heavy smokers' chances of quitting successfully. The analysis is the first of its kind that focuses on the 8% of American smokers who smoke the most and who have the most difficulty quitting.
In the studies, 28.4% of the heaviest smokers using the NicoDerm CQ patch were still not smoking after 6 months, compared to 8.1% using placebo. With the Commit lozenge, 22.1% of the heaviest smokers were still not smoking compared to 6.3% using placebo. The findings were consistent across the two studies reviewed, even though they used different selection criteria, methodology, and cessation treatment methods.
"Nearly ten percent of smokers smoke more than two packs a day," said Saul Shiffman, Ph.D., lead author of the study. "Many of these heavy smokers may not believe that stop-smoking products can help them. The drastic difference in quit rates for heavy and highly dependent smokers who used NicoDerm CQ or Commit, compared to placebo, shows that these products can play a huge role in helping those who most need to quit."
Medicinal nicotine works by weaning smokers off their nicotine addiction without exposing them to the more than 4,000 chemicals and at least 69 known or suspected carcinogens found in tobacco smoke. Smokers can choose which medicinal nicotine product to use based upon their individual smoking habits, including how much they smoke. GSK Consumer Healthcare offers the widest range of proven products including two starting strengths of clear and opaque NicoDerm CQ; two strengths of the Commit lozenge; and two strengths, four flavors and two formulas of Nicorette® gum. GSK Consumer Healthcare's stop-smoking products have helped more than 2 million Americans stop smoking by providing low, safe doses of nicotine to ease withdrawal from cigarettes.
To provide additional support to the proven medicine in these products, smokers can receive specific tips for success and advice about staying smoke- free on the GSK Consumer Healthcare Web site quit.
About GlaxoSmithKline Consumer Healthcare
GlaxoSmithKline Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well- known brands include the leading smoking cessation products, Nicorette®, NicoDerm® and Commit®, as well as many medicine cabinet staples, Abreva®, Aquafresh®, Sensodyne® and Tums®. GlaxoSmithKline Consumer Healthcare continues to develop innovative products to help all smokers find their best support system and achieve their goal of being cigarette free.
GlaxoSmithKline is one of the world's leading research-based pharmaceutical and consumer healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
About the Journal of Substance Abuse Treatment
Journal of Substance Abuse Treatment is an internationally recognized journal that features original research articles that are meaningful to the treatment of nicotine, alcohol, and other drugs of dependence. It is published by Elsevier, the world's largest publisher of peer-reviewed scientific journals. The Editor-in-Chief is Dr. A. Thomas McLellan of the Treatment Research Institute in Philadelphia. Abstracts are available online at journals.elsevierhealth/periodicals/satVirginia Bader, Porter Novelli
Melissa Burslie, Porter Novelli
Malesia Dunn, GlaxoSmithKline Consumer
View drug information on NicoDerm CQ.